Active, not recruitingPhase 2NCT03337919

ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Studying Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University College, London
Principal Investigator
Graham Collins
Oxford University Hospitals NHS Trust
Intervention
Nivolumab(drug)
Enrollment
78 target
Eligibility
16 years · All sexes
Timeline
2018 – 2026

Study locations (10)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03337919 on ClinicalTrials.gov

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Hodgkin lymphoma →

← Back to all trials